Item

Outcomes and characteristics of non-melanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Laing, Heather
; 
Garg, Mamta
; 
Wadelin, Frances
Abstract
Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.
MIDER Authors
Citations
Altmetric:
Date
2023-11-14
Type
Article
Subject
Non-melanoma skin cancers, ruxolitinib, MPN patients
Collections
Haematology
Show all metadata
Citation
Rampotas, A., Carter-Brzezinski, L., Somervaille, T. C., Forryan, J., Panitsas, F. P., Harrison, C. N., Witherall, R., Innes, A. J., Wallis, L., Butt, N. M., Psaila, B., Mead, A. J., Carter, M., Godfrey, A. L., Laing, H., Garg, M., Francis, S., Ewing, J., Teh, C. H., Cowan, H. B., … Lambert, J. (2023). Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib. Blood, blood.2023022345. Advance online publication. https://doi.org/10.1182/blood.2023022345
Journal / Source Title
DOI
URI
https://mider.dspace7.openrepository.com/handle/20.500.12904/17898
PMID
Publisher
Publisher’s URL
Publisher’s statement
Note / Copyright